SCHEMBL29508714

SCHEMBL29508714

NCCCC[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](N)Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O

nearest known ligand 0.66

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ GHSR Q92847 5/20 0.64
▸ NPY1R P25929 3/20 0.63
▸ NPY2R P49146 3/20 0.63
▸ NPY4R P50391 3/20 0.63
▸ ERAP2 Q6P179 2/20 0.60
▸ ERAP1 Q9NZ08 2/20 0.60
▸ LNPEP Q9UIQ6 1/20 0.60
▸ IL1RN P18510 1/20 0.59
▸ UTS2R Q9UKP6 1/20 0.58
▸ OPRM1 P35372 1/20 0.57
▸ OPRD1 P41143 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29508679 0.98 GHSR (0.64) GHSRNPY1RNPY2RNPY4RERAP2
SCHEMBL31731732 0.97 GHSR (0.62) GHSRNPY1RNPY2RNPY4RERAP2
SCHEMBL29508662 0.97 GHSR (0.63) GHSRNPY1RNPY2RNPY4RERAP2
SCHEMBL29896929 0.95 GHSR (0.63) GHSRNPY1RNPY2RNPY4RERAP2
SCHEMBL29508663 0.95 NPY1R (0.65) GHSRNPY1RNPY2RNPY4RERAP2
SCHEMBL29577431 0.94 NPY1R (0.66) GHSRNPY1RNPY2RNPY4RERAP2
SCHEMBL29578675 0.94 NPY1R (0.66) GHSRNPY1RNPY2RNPY4RERAP2
SCHEMBL30179569 0.94 GHSR (0.64) GHSRNPY1RNPY2RNPY4RERAP2
SCHEMBL30518046 0.94 GHSR (0.60) GHSRNPY1RNPY2RNPY4RERAP2
SCHEMBL29425246 0.93 GHSR (0.60) GHSRNPY1RNPY2RNPY4RERAP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220389057-A1 ENDOCYTOSIS ROUTING SEQUENCE PEPTIDE FOR CELL DELIVERY SYSTEMS SZTE TTC ZÁRTKÖRUEN MUKÖDO RÉSZVÉNYTÁRSASÁG (HU) 2022-12-08 — — US claimed
EP-3980439-A1 ENDOCYTOSIS ROUTING SEQUENCE PEPTIDE FOR CELL DELIVERY SYSTEMS Szegedi Tudományegyetem (HU) 2022-04-13 — — EP claimed
US-20220389057-A1 ENDOCYTOSIS ROUTING SEQUENCE PEPTIDE FOR CELL DELIVERY SYSTEMS SZTE TTC ZÁRTKÖRUEN MUKÖDO RÉSZVÉNYTÁRSASÁG (HU) 2022-12-08 — — US disclosed
EP-3980439-A1 ENDOCYTOSIS ROUTING SEQUENCE PEPTIDE FOR CELL DELIVERY SYSTEMS Szegedi Tudományegyetem (HU) 2022-04-13 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220389057-A1 ENDOCYTOSIS ROUTING SEQUENCE PEPTIDE FOR CELL DELIVERY SYSTEMS MARCKS, SORT1, PICALM GHSR 1240/4885NPY1R 559/4885NPY2R 399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback